Clinical trial
Phase 1/2a Dose Escalation Study of ANPD001 in Sporadic Parkinson Disease
NCT06344026 is registered in ClinicalTrials.gov with Aspen Neuroscience as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase 1/2a Dose Escalation Study of ANPD001 in Sporadic Parkinson Disease
- Lead sponsor
- Aspen Neuroscience
- Phase
- Phase 1
- Overall status
- Enrolling by invitation
- Start date
- January 23, 2024
- Completion date
- April 30, 2030
- Enrollment
- 9 (estimated)
- Sites
- 9
Conditions
As the registry lists them; a condition with its own page is linked.